(Q41386107)

30 September 2017

1 reference

title

Is abdomino-pelvic radiation therapy the optimal treatment for completely resected stage I and II high risk ovarian cancer? (English)

1 reference

30 September 2017

1 reference

1

1 reference

30 September 2017

Bolis G

2

1 reference

30 September 2017

Ferraris C

series ordinal

3

1 reference

30 September 2017

Parazzini F

series ordinal

4

1 reference

30 September 2017

Bolla M

series ordinal

5

1 reference

30 September 2017

publication date

1 January 1997

1 reference

European Journal of Cancer

30 September 2017

published in

1 reference

30 September 2017

volume

33

1 reference

30 September 2017

issue

1

1 reference

30 September 2017

page(s)

12-19

1 reference

Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Is Stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Abdominopelvic radiotherapy in ovarian cancer. A 10-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Analysis of postoperative radiation therapy in stage I through III epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Postoperative radiation therapy for epithelial ovarian cancer: the curative role based on a 24-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Radiation dose-response of human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Dose-response relationship for radiation therapy of subclinical disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

The West Midlands epithelial ovarian cancer adjuvant therapy trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in 'high-risk' epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Whole abdominal radiotherapy following cytoreductive surgery and chemotherapy in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Total abdominal irradiation in stage I and II carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Postoperative abdominopelvic radiation therapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

'Moderate-risk' ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900429-7

7 January 2021

10.1016/S0959-8049(96)00429-7

Identifiers

DOI

1 reference

30 September 2017

1 reference